EasySep™ Human Naïve CD8+ T Cell Isolation Kit II

总览

使用EasySep™人Naïve CD8+ T细胞分选试剂盒 II，通过免疫磁珠负选，可轻松高效地从新鲜人外周血单个核细胞（PBMC）样本中分离出高纯度初始CD8+ T细胞(CD8+CD45RA+CCR7+且CD45RO-CD57-CD56-)。EasySep™结合了单克隆抗体的特异性和无柱磁性系统的简便性，迄今已广泛应用于发表的研究中超过20年。

在此 EasySep™负选过程中，非目标细胞通过抗体复合物与磁珠标记。表达以下标记物的非目的细胞通过抗体复合物和磁珠标记被靶向去除：CD4、CD14、CD16、CD19、CD20、CD36、CD56、CD94、CD123、CD244、IgM、GlyA、TCRγδ、CD45RO及CD57。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，接着简单地将目的细胞倾倒或吸取至一个新的试管中。仅需11分钟磁珠分选，获得的初始CD8+ T细胞即可用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

该产品可替代EasySep™人CD8+ T细胞富集试剂盒 (产品号 #19158) 以进行更快的细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。或选择即用型、符合伦理规范的冻存人外周血原代CD8+CD45RA+ T细胞，该细胞通过EasySep™人Naïve CD8+ T细胞分选试剂盒II分离获得。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

磁极兼容性
• EasySep™磁极（产品号 #18000） • “The Big Easy” EasySep™磁极（产品号 #18001） • EasyEights™ EasySep™磁极（产品号 #18103） • RoboSep™-S（产品号 #21000）

分类
细胞分选试剂盒

细胞类型
T 细胞，T 细胞，CD8+

种属
人

样本来源
PBMC

分选方法
负选

应用
细胞分选

品牌
EasySep，RoboSep

研究领域
免疫

查看更多显示更少

实验数据

Figure 1. Typical EasySep™ Human Naive CD8 T Cell Isolation Profile

Starting with fresh PBMCs, the naïve CD8+ T cell content (CD8+CD45RA+CCR7+ and CD45RO-CD57-CD56-) of the isolated fraction is typically 93.7 ± 2.4% (mean ± SD), using the purple EasySep™ Magnet. In the above example, the purities of the start and final isolated fractions are 6.8% and 94.2%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968RF

Lot #

All

Language

English

Document Type

Product Information Sheet

Product Name

EasySep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for T Cell Research

Cell Sourcing

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Workflow Stages for T Cell Engineering

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Cell Cryopreservation

相关材料与文献

Induction of memory-like CD8+ T cells and CD4+ T cells from human naive T cells in culture. Y. Tokumoto et al. Clinical and experimental immunology 2022 jan

Abstract

Memory T cells are crucial players in vertebrate adaptive immunity but their development is incompletely understood. Here, we describe a method to produce human memory-like T cells from naive human T cells in culture. Using commercially available human T-cell differentiation kits, both purified naive CD8+ T cells and purified naive CD4+ T cells were activated via T-cell receptor signaling and appropriate cytokines for several days in culture. All the T-cell activators were then removed from the medium and the cultures were continued in hypoxic condition (1% O2 atmosphere) for several more days; during this period, most of the cells died, but some survived in a quiescent state for a month. The survivors had small round cell bodies, expressed differentiation markers characteristic of memory T cells and restarted proliferation when the T-cell activators were added back. We could also induce memory-like T cells from naive human T cells without hypoxia, if we froze the activated T cells or prepared the naive T cells from chilled filter buffy coats.

View publication

Tbc1d10c is a selective, constitutive suppressor of the CD8 T-cell anti-tumor response. A. O. Cohen et al. Oncoimmunology 2022

Abstract

Cancer immunotherapy approaches target signaling pathways that are highly synonymous between CD4 and CD8 T-cell subsets and, therefore, often stimulate nonspecific lymphocyte activation, resulting in cytotoxicity to otherwise healthy tissue. The goal of our study was to identify intrinsic modulators of basic T lymphocyte activation pathways that could discriminately bolster CD8 anti-tumor effector responses. Using a Tbc1d10c null mouse, we observed marked resistance to a range of tumor types conferred by Tbc1d10c deficiency. Moreover, tumor-bearing Tbc1d10c null mice receiving PD-1 or CTLA-4 monotherapy exhibited a 33% or 90% cure rate, respectively. While Tbc1d10c was not expressed in solid tumor cells, Tbc1d10c disruption selectively augmented CD8 T-cell activation and cytotoxic effector responses and adoptive transfer of CD8 T cells alone was sufficient to recapitulate Tbc1d10c null tumor resistance. Mechanistically, Tbc1d10c suppressed CD8 T-cell activation and anti-tumor function by intersecting canonical NF-$\kappa$B pathway activation via regulation of Map3k3-mediated IKK$\beta$ phosphorylation. Strikingly, none of these cellular or molecular perturbations in the NF-$\kappa$B pathway were featured in Tbc1d10c null CD4 T cells. Our findings identify a Tbc1d10c-Map3k3-NF-$\kappa$B signaling axis as a viable therapeutic target to promote CD8 T-cell anti-tumor immunity while circumventing CD4 T cell-associated cytotoxicity and NF-$\kappa$B activation in tumor cells.

View publication

Efficient derivation of chimeric-antigen receptor-modified TSCM cells. E. Kranz et al. Frontiers in immunology 2022

Abstract

Chimeric-antigen receptor (CAR) T-cell immunotherapy employs autologous-T cells modified with an antigen-specific CAR. Current CAR-T manufacturing processes tend to yield products dominated by effector T cells and relatively small proportions of long-lived memory T cells. Those few cells are a so-called stem cell memory T (TSCM) subset, which express na{\{i}}ve T-cell markers and are capable of self-renewal and oligopotent differentiation into effector phenotypes. Increasing the proportion of this subset may lead to more effective therapies by improving CAR-T persistence; however there is currently no standardized protocol for the effective generation of CAR-TSCM cells. Here we present a simplified protocol enabling efficient derivation of gene-modified TSCM cells: Stimulation of na{\"{i}}ve CD8+ T cells with only soluble anti-CD3 antibody and culture with IL-7 and IL-15 was sufficient for derivation of CD8+ T cells harboring TSCM phenotypes and oligopotent capabilities. These in-vitro expanded TSCM cells were engineered with CARs targeting the HIV-1 envelope protein as well as the CD19 molecule and demonstrated effector activity both in vitro and in a xenograft mouse model. This simple protocol for the derivation of CAR-TSCM cells may facilitate improved adoptive immunotherapy."

View publication

View All Publications

EasySep™人Naïve CD8+ T细胞分选试剂盒 II

产品号 #17968

产品号 #17968RF

产品号 #（选择产品）

产品号 #17968_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

种属	Human
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
样本来源	PBMC
Selection Method	Negative

EasySep™人Naïve CD8+ T细胞分选试剂盒 II

产品号 #17968

产品号 #17968RF

产品号 #（选择产品）

产品号 #17968_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (9)

文献 (3)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台